Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
Octreotide, somatostatin and pentoxyfilline commercially available drugs that are used in
 various clinical situations. They are safe and known for years. Octreotide and somatostatin
 have been used in many studies for the prophylaxis and treatment of pancreatitis and
 post-ERCP pancreatitis, while pentoxyfilline has shown effect on patients with alcoholic
 hepatitis, obstructive vasculitis etc. The aim of the study is to evaluate the efficacy of
 any of those treatments for the prophylaxis and treatment of post-ERCP pancreatitis. In
 addition some molecular markers of acute and chronic inflammation will be measured before and
 after the endoscopic procedures according to the study protocol.
Inclusion Criteria:

 -  patients undergoing endoscopic retrograde cholangiopancreatography

 Exclusion Criteria:

 -  children, pregnant or breastfeeding women

 -  patients with coagulation disorders

 -  inability to access the papilla of Vater due to technical difficulties (previous
 surgery, malignant obstruction)